Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis- evidence summary (ES29)

Review notes this can be self-administered at home with appropriate training & is most likely to be used in people already established on IV infliximab (IVI) or have stable disease but difficulty attending hospital or in whom risk of attending hospital for IVI outweighs benefits.


National Institute for Health and Care Excellence